External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

NASPGHAN 2026

-
12:00 AM
Duration 120mins San Diego, USA
Rationale and Design of the AMETRINE-PEDS and SIBERITE-PEDS Phase III Treat-Through Studies Evaluating Afimkibart in Children with Moderately to Severely Active UC and CD
Sheila Shapouri, Jeffrey Hyams, Fatima Abbas, Steven Levitte, Pascal Espie, Jinnie Ko, Margaret Neighbors, KT Park
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon